N-(6-(2-((2-tert-butylphenyl)sulfanyl)-4-pyrimidinyl)-1,3-benzothiazol-2-yl)acetamide | 1112979-49-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: N-(6-(2-((2-tert-butylphenyl)sulfanyl)-4-pyrimidinyl)-1,3-benzothiazol-2-yl)acetamide
• 英文别名: N-[6-[2-(2-tert-butylphenyl)sulfanylpyrimidin-4-yl]-1,3-benzothiazol-2-yl]acetamide
• CAS: 1112979-49-3
• 化学式: C₂₃H₂₂N₄OS₂
• 分子量: 434.586
• InChiKey: LOMWFHBXVUHQFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  121
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• PI3 kinase modulators and methods of use
  申请人：Booker Shon

  公开号：US20090054405A1

  公开（公告）日：2009-02-26

  The present invention comprises a new class of compounds capable of modulating the activity of PI3 kinase and, accordingly, useful for treatment of PI3 kinase mediated diseases, including melanomas, carcinomas and other cancer-related conditions. The compounds have a general Formula I wherein each of A 1 , A 2 , A 3 , A 4 , X, R 1 and R 2 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of PI3 kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

  本发明涉及一类新的化合物，能够调节PI3激酶的活性，因此对于治疗PI3激酶介导的疾病，包括黑色素瘤、癌瘤和其他与癌症相关的疾病非常有用。这些化合物具有通式I，其中A1、A2、A3、A4、X、R1和R2均在此定义。本发明还涉及制药组合物、治疗PI3激酶介导的疾病的方法，以及用于制备本发明化合物的中间体和过程。
• PI3 KINASE MODULATORS AND METHODS OF USE
  申请人：Amgen, Inc

  公开号：EP2183232A2

  公开（公告）日：2010-05-12
• US7928140B2
  申请人：——

  公开号：US7928140B2

  公开（公告）日：2011-04-19
• [EN] PI3 KINASE MODULATORS AND METHODS OF USE<br/>[FR] MODULATEUR DE LA PI3 KINASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2009017822A2

  公开（公告）日：2009-02-05

  The present invention comprises a new class of compounds capable of modulating the activity of PI3 kinase and, accordingly, useful for treatment of PI3 kinase mediated diseases, including melanomas, carcinomas and other cancer-related conditions. The compounds have a general Formula I wherein each of A1, A2, A3, A4, X, R1 and R2 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of PI3 kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.